Nonsmall Cell Lung Cancer
Conditions
Keywords
Non-Small Cell Lung Cancer, Multidisciplinary Team, Locally Deployed AI Model, Large Language Model, Treatment Decision-Making
Brief summary
The goal of this clinical trial is to evaluate the effectiveness and safety of a locally deployed artificial intelligence (AI) decision-support model in the multidisciplinary team (MDT) process for patients with non-small cell lung cancer (NSCLC). The main questions it aims to answer : What is the level of agreement between treatment recommendations generated by the AI model and those made by a traditional MDT? How often do clinicians modify their final treatment decision after reviewing the AI model's recommendation? Researchers will compare treatment plans from the traditional MDT (Arm 1), the AI model (Arm 2), and the clinician's final decision after reviewing the AI output (Arm 3) to assess consistency, decision modification rates, and clinical efficiency. Participants will: Have their clinical, imaging, and molecular data submitted to both the traditional MDT and the AI model for independent treatment recommendations Receive a final treatment plan determined by clinicians after reviewing both recommendations, with follow-up for safety and survival outcomes
Interventions
DIAGNOSTIC_TESTTreat Regimen
The impact of artificial intelligence on clinicians' treatment plans
Sponsors
Wen-zhao ZHONG
Guangdong Provincial People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years; 2. MDT (Multidisciplinary Team) discussion deems a systemic treatment plan necessary; 3. Complete clinical, imaging, and molecular pathological data.
Exclusion criteria
1. Stage I patients; 2. Diagnosed with a thoracic tumor other than NSCLC; 3. Lack of detailed medical data, or missing data;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Consistency rate | Baseline(MDT 1 Day) | Consistency rate between Option 1 and Option 2 (calculated using Kappa value). Consistency rate between Option 1 and Option 3 (decision modification rate). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MDT Discussion Process Time | Baseline(MDT Day 1) | Time from start to end of multidisciplinary team (MDT) discussion, measured immediately after MDT end. |
| Quality of AI Recommendations | Baseline(MDT Day 1) | Physician-rated quality of AI recommendations using a Likert 5-point scale (1 = very poor, 5 = excellent). |
| Clinical Acceptability of AI | Baseline(MDT Day 1) | Physician-rated clinical acceptability of AI recommendations using a Likert 5-point scale (1 = unacceptable, 5 = fully acceptable). |
| MDT Discussion Efficiency | Baseline(MDT Day 1) | Physician-rated efficiency of MDT discussion process aided by AI using a Likert 5-point scale (1 = very inefficient, 5 = very efficient). |
| Process Convenience | Baseline(MDT Day 1) | Physician-rated convenience of the AI-integrated workflow using a Likert 5-point scale (1 = very inconvenient, 5 = very convenient). |
| Added Value to Clinical Decision | Baseline(MDT Day 1) | Physician-rated added value of AI to clinical decision-making using a Likert 5-point scale (1 = no added value, 5 = significant added value). |
| Learning and Training Value | Baseline(MDT Day 1) | Physician-rated learning and training value of AI system using a Likert 5-point scale (1 = no value, 5 = high value). |
| Overall Satisfaction | Baseline(MDT Day 1) | Physician-rated overall satisfaction with AI-assisted MDT using a Likert 5-point scale (1 = very dissatisfied, 5 = very satisfied). |
| Willingness to Use in Future | Baseline(MDT Day 1) | Physician-rated willingness to use AI system in future clinical practice using a Likert 5-point scale (1 = definitely not willing, 5 = definitely willing). |
| Disease-Free Survival (DFS) | 3 years | Time from treatment initiation to disease recurrence or death from any cause, assessed every 3-6 months during 2-3 years follow-up. |
| Progression-Free Survival (PFS) | 3 years | Time from treatment initiation to disease progression or death from any cause, assessed every 3-6 months during 2-3 years follow-up. |
| Overall Survival (OS) | 3 years | Time from treatment initiation to death from any cause, assessed every 3-6 months during 2-3 years follow-up. |
Countries
China
Contacts
CONTACTqing liang, Dr.
Outcome results
None listed